United Therapeutics Past Earnings Performance
Past criteria checks 3/6
United Therapeutics has been growing earnings at an average annual rate of 30.7%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 13.7% per year. United Therapeutics's return on equity is 18.2%, and it has net margins of 40.3%.
Key information
30.7%
Earnings growth rate
29.6%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 13.7% |
| Return on equity | 18.2% |
| Net Margin | 40.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How United Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,756 | 1,111 | 607 | 499 |
| 30 Jun 24 | 2,617 | 1,069 | 581 | 480 |
| 31 Mar 24 | 2,498 | 1,051 | 533 | 429 |
| 31 Dec 23 | 2,328 | 985 | 476 | 408 |
| 30 Sep 23 | 2,204 | 900 | 499 | 351 |
| 30 Jun 23 | 2,111 | 872 | 470 | 332 |
| 31 Mar 23 | 1,981 | 728 | 481 | 337 |
| 31 Dec 22 | 1,936 | 727 | 473 | 323 |
| 30 Sep 22 | 1,860 | 707 | 448 | 312 |
| 30 Jun 22 | 1,789 | 631 | 458 | 324 |
| 31 Mar 22 | 1,768 | 687 | 429 | 304 |
| 31 Dec 21 | 1,686 | 476 | 466 | 410 |
| 30 Sep 21 | 1,655 | 462 | 499 | 450 |
| 30 Jun 21 | 1,591 | 471 | 451 | 440 |
| 31 Mar 21 | 1,506 | 405 | 444 | 456 |
| 31 Dec 20 | 1,483 | 515 | 421 | 358 |
| 30 Sep 20 | 1,410 | 469 | 364 | 345 |
| 30 Jun 20 | 1,431 | 430 | 402 | 362 |
| 31 Mar 20 | 1,443 | 528 | 336 | 350 |
| 31 Dec 19 | 1,449 | -104 | 335 | 1,174 |
| 30 Sep 19 | 1,519 | -92 | 313 | 1,199 |
| 30 Jun 19 | 1,530 | -118 | 324 | 1,214 |
| 31 Mar 19 | 1,601 | -150 | 367 | 1,220 |
| 31 Dec 18 | 1,628 | 589 | 269 | 358 |
| 30 Sep 18 | 1,711 | 543 | 348 | 333 |
| 30 Jun 18 | 1,744 | 713 | 285 | 287 |
| 31 Mar 18 | 1,744 | 484 | 270 | 264 |
| 31 Dec 17 | 1,725 | 418 | 333 | 265 |
| 30 Sep 17 | 1,670 | 509 | 311 | 218 |
| 30 Jun 17 | 1,632 | 395 | 363 | 209 |
| 31 Mar 17 | 1,600 | 657 | 368 | 184 |
| 31 Dec 16 | 1,599 | 714 | 319 | 148 |
| 30 Sep 16 | 1,595 | 708 | 326 | 157 |
| 30 Jun 16 | 1,573 | 1,011 | 209 | 120 |
| 31 Mar 16 | 1,507 | 904 | 246 | 135 |
| 31 Dec 15 | 1,466 | 652 | 453 | 245 |
| 30 Sep 15 | 1,407 | 663 | 385 | 241 |
| 30 Jun 15 | 1,351 | 173 | 604 | 350 |
| 31 Mar 15 | 1,327 | 186 | 562 | 340 |
| 31 Dec 14 | 1,289 | 340 | 381 | 243 |
| 30 Sep 14 | 1,231 | 194 | 458 | 293 |
| 30 Jun 14 | 1,203 | 282 | 350 | 246 |
| 31 Mar 14 | 1,161 | 250 | 353 | 261 |
| 31 Dec 13 | 1,117 | 175 | 394 | 299 |
Quality Earnings: U2TH34 has high quality earnings.
Growing Profit Margin: U2TH34's current net profit margins (40.3%) are lower than last year (40.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: U2TH34 has become profitable over the past 5 years, growing earnings by 30.7% per year.
Accelerating Growth: U2TH34's earnings growth over the past year (23.5%) is below its 5-year average (30.7% per year).
Earnings vs Industry: U2TH34 earnings growth over the past year (23.5%) exceeded the Biotechs industry 4%.
Return on Equity
High ROE: U2TH34's Return on Equity (18.2%) is considered low.